Cargando…

Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis

INTRODUCTION: Several studies have reported on hepatitis E virus (HEV) prevalence in various regions of China, but the results vary widely. Herein, we conducted a systematic review and meta-analysis to assess the seroprevalence, RNA-positive rate, genotype distribution of HEV in China, and its risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Kexin, Wu, Xiaoyue, Yang, Mengya, Chen, Can, Zhang, Xiaobao, Jiang, Daixi, Du, Yuxia, Chen, Mengsha, You, Yue, Zhou, Wenkai, Qi, Jiaxing, Chen, Dingmo, Yan, Rui, Miao, Ziping, Yang, Shigui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512461/
https://www.ncbi.nlm.nih.gov/pubmed/37744517
http://dx.doi.org/10.3389/fpubh.2023.1243408
_version_ 1785108364449021952
author Cao, Kexin
Wu, Xiaoyue
Yang, Mengya
Chen, Can
Zhang, Xiaobao
Jiang, Daixi
Du, Yuxia
Chen, Mengsha
You, Yue
Zhou, Wenkai
Qi, Jiaxing
Chen, Dingmo
Yan, Rui
Miao, Ziping
Yang, Shigui
author_facet Cao, Kexin
Wu, Xiaoyue
Yang, Mengya
Chen, Can
Zhang, Xiaobao
Jiang, Daixi
Du, Yuxia
Chen, Mengsha
You, Yue
Zhou, Wenkai
Qi, Jiaxing
Chen, Dingmo
Yan, Rui
Miao, Ziping
Yang, Shigui
author_sort Cao, Kexin
collection PubMed
description INTRODUCTION: Several studies have reported on hepatitis E virus (HEV) prevalence in various regions of China, but the results vary widely. Herein, we conducted a systematic review and meta-analysis to assess the seroprevalence, RNA-positive rate, genotype distribution of HEV in China, and its risk factors. METHODS: We included 208 related studies involving 1,785,569 participants published between 1997 and 2022. Random-effects models were used to pool prevalence, and subgroup analyses were conducted by population, gender, age, study period, regions, and rural–urban distribution. The meta regression models and pooled odds ratios (OR) were performed to identify risk factors for HEV infections. RESULTS: The pooled anti-HEV IgG, IgM, and Ag seroprevalence, and RNA detection rates in China from 1997 to 2022 were 23.17% [95% confidence interval (CI): 20.23–26.25], 0.73% (95% CI: 0.55–0.93), 0.12% (95% CI: 0.01–0.32), and 6.55% (95% CI: 3.46–12.05), respectively. The anti-HEV IgG seropositivity was higher in the occupational population (48.41%; 95% CI: 40.02–56.85) and older adult aged 50–59 years (40.87%; 95% CI: 31.95–50.11). The dominant genotype (GT) of hepatitis E in China was GT4. Notably, drinking non-tap water (OR = 1.82; 95% CI: 1.50–2.20), consumption of raw or undercooked meat (OR = 1.47; 95% CI: 1.17–1.84), and ethnic minorities (OR = 1.50; 95% CI: 1.29–1.73) were risk factors of anti-HEV IgG seroprevalence. DISCUSSIONS: Overall, the prevalence of hepatitis E was relatively high in China, especially among older adults, ethnic minorities, and humans with occupational exposure to pigs. Thus, there is a need for preventive measures, including HEV infection screening and surveillance, health education, and hepatitis E vaccine intervention in high-risk areas and populations. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023397036.
format Online
Article
Text
id pubmed-10512461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105124612023-09-22 Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis Cao, Kexin Wu, Xiaoyue Yang, Mengya Chen, Can Zhang, Xiaobao Jiang, Daixi Du, Yuxia Chen, Mengsha You, Yue Zhou, Wenkai Qi, Jiaxing Chen, Dingmo Yan, Rui Miao, Ziping Yang, Shigui Front Public Health Public Health INTRODUCTION: Several studies have reported on hepatitis E virus (HEV) prevalence in various regions of China, but the results vary widely. Herein, we conducted a systematic review and meta-analysis to assess the seroprevalence, RNA-positive rate, genotype distribution of HEV in China, and its risk factors. METHODS: We included 208 related studies involving 1,785,569 participants published between 1997 and 2022. Random-effects models were used to pool prevalence, and subgroup analyses were conducted by population, gender, age, study period, regions, and rural–urban distribution. The meta regression models and pooled odds ratios (OR) were performed to identify risk factors for HEV infections. RESULTS: The pooled anti-HEV IgG, IgM, and Ag seroprevalence, and RNA detection rates in China from 1997 to 2022 were 23.17% [95% confidence interval (CI): 20.23–26.25], 0.73% (95% CI: 0.55–0.93), 0.12% (95% CI: 0.01–0.32), and 6.55% (95% CI: 3.46–12.05), respectively. The anti-HEV IgG seropositivity was higher in the occupational population (48.41%; 95% CI: 40.02–56.85) and older adult aged 50–59 years (40.87%; 95% CI: 31.95–50.11). The dominant genotype (GT) of hepatitis E in China was GT4. Notably, drinking non-tap water (OR = 1.82; 95% CI: 1.50–2.20), consumption of raw or undercooked meat (OR = 1.47; 95% CI: 1.17–1.84), and ethnic minorities (OR = 1.50; 95% CI: 1.29–1.73) were risk factors of anti-HEV IgG seroprevalence. DISCUSSIONS: Overall, the prevalence of hepatitis E was relatively high in China, especially among older adults, ethnic minorities, and humans with occupational exposure to pigs. Thus, there is a need for preventive measures, including HEV infection screening and surveillance, health education, and hepatitis E vaccine intervention in high-risk areas and populations. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023397036. Frontiers Media S.A. 2023-09-07 /pmc/articles/PMC10512461/ /pubmed/37744517 http://dx.doi.org/10.3389/fpubh.2023.1243408 Text en Copyright © 2023 Cao, Wu, Yang, Chen, Zhang, Jiang, Du, Chen, You, Zhou, Qi, Chen, Yan, Miao and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Cao, Kexin
Wu, Xiaoyue
Yang, Mengya
Chen, Can
Zhang, Xiaobao
Jiang, Daixi
Du, Yuxia
Chen, Mengsha
You, Yue
Zhou, Wenkai
Qi, Jiaxing
Chen, Dingmo
Yan, Rui
Miao, Ziping
Yang, Shigui
Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
title Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
title_full Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
title_fullStr Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
title_full_unstemmed Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
title_short Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
title_sort prevalence of hepatitis e virus in china from 1997 to 2022: a systematic review and meta-analysis
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512461/
https://www.ncbi.nlm.nih.gov/pubmed/37744517
http://dx.doi.org/10.3389/fpubh.2023.1243408
work_keys_str_mv AT caokexin prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT wuxiaoyue prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT yangmengya prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT chencan prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT zhangxiaobao prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT jiangdaixi prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT duyuxia prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT chenmengsha prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT youyue prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT zhouwenkai prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT qijiaxing prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT chendingmo prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT yanrui prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT miaoziping prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis
AT yangshigui prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis